Scholarlink

<p><i>Klebsiella pneumoniae</i> (<i>K. pneumoniae</i>) is a WHO priority pathogen, with multidrug-resistant (MDR) and carbapenem-resistant (CRKP) strains causing severe, often untreatable urinary tract infections (UTIs). The therapeutic impasse has reignited interest in bacteriophage (phage) therapy, a precision antibacterial approach that uses viruses to selectively lyse bacterial pathogens. The potential of phage therapy for MDR <i>K. pneumoniae</i> UTIs is critically evaluated in this review. We summarize the underlying biological rationale, concentrating on phage-mediated lysis and biofilm disruption. We then examine the translational landscape, comparing promising preclinical and compassionate-use data with the limited outcomes from early controlled clinical trials. A key theme is the critical need for strategic frameworks to guide clinical deployment, including rational cocktail design, phage-antibiotic synergy (PAS), and personalized approaches. Lastly, we list the main issues that must be addressed to incorporate phage therapy into the clinical arsenal against these powerful infections.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Deploying bacteriophage combinatorial therapy to eradicate resistant Klebsiella pneumoniae UTIs: innovative and personalized phage therapy

  • 期刊论文

  • 发表日期：

    2026年3月10日

查看全文
  • Usamah Sayed,
  • Waleed K. Abdulsahib,
  • Wael Waleed Mustafa,
  • H. Malathi,
  • Rajashree Panigrahi,
  • Y. Swarna Latha,
  • Vipasha Sharma,
  • Aashna Sinha,
  • Nigina Khalikova

摘要

Klebsiella pneumoniae (K. pneumoniae) is a WHO priority pathogen, with multidrug-resistant (MDR) and carbapenem-resistant (CRKP) strains causing severe, often untreatable urinary tract infections (UTIs). The therapeutic impasse has reignited interest in bacteriophage (phage) therapy, a precision antibacterial approach that uses viruses to selectively lyse bacterial pathogens. The potential of phage therapy for MDR K. pneumoniae UTIs is critically evaluated in this review. We summarize the underlying biological rationale, concentrating on phage-mediated lysis and biofilm disruption. We then examine the translational landscape, comparing promising preclinical and compassionate-use data with the limited outcomes from early controlled clinical trials. A key theme is the critical need for strategic frameworks to guide clinical deployment, including rational cocktail design, phage-antibiotic synergy (PAS), and personalized approaches. Lastly, we list the main issues that must be addressed to incorporate phage therapy into the clinical arsenal against these powerful infections.

Graphical abstract